Clinical Trial Update: Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

This is a completed Phase 1/2 clinical trial from MD Anderson evaluating AFM13 and AFM13-NK in patients with recurrent or refractory CD30-positive Hodgkin lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• B-cell Non-hodgkin Lymphoma
• Classic Hodgkin Lymphoma
• Mycosis Fungoides
• Peripheral T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• AFM13
• AFM13-NK

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED